SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. The SITC Lymphoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG will provide recommendations regarding FDA-approved immunotherapies for Hodkin lymphoma and multiple subtypes of non-Hodgkin lymphoma, including rituximab, brentuximab vedotin and axicabtagene ciloleucel, as well as discussion of promising emerging treatment modalities and patient quality of life issues.
Published December 24, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma"
July 7, 2021, 5:30-6:30 pm ETCase Studies in Immunotherapy for the Treatment of Lymphoma This high-level webinar is designed so that attendees will be able to execute the use of immunotherapy with increased confidence, plan management strategies for difficult cases, and identify and discuss areas of controversy in the immunotherapy field.Webinar Faculty:
Practical Management Pearls for Immunotherapy for the Treatment of LymphomaThis advanced webinar is designed for attendees to be able to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, among other learning outcomes. SITC hosted this session on June 21, 2021, featuring members of the Cancer Immunotherapy Guideline – Lymphoma Expert Panel. A free SITC Connect account is required to view the on-demand webinars (you will be prompted to create a SITC Connect account if you don’t already have one).VIEW ON-DEMAND WEBINAROverview of Immunotherapy for the Treatment of Lymphoma Learn more about immunotherapy treatment standards for lymphoma and hear more about the the clinical practice guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma" in this webinar. SITC hosted this session on January 25, 2021, featuring members of the Cancer Immunotherapy Guideline – Lymphoma Expert Panel. A free SITC Connect account is required to view the on-demand webinars (you will be prompted to create a SITC Connect account if you don’t already have one).
VIEW ON-DEMAND WEBINAR
Sherry Adkins, RN, MSN, CNS, ANP-C — The University of Texas MD Anderson Cancer Center
Stephen M. Ansell, MD, PhD — Mayo Clinic Cancer Center
Joshua Brody, MD — Icahn School of Medicine at Mount Sinai
Mitchell S. Cairo, MD — New York Medical College At Maria Fareri Children's Hospital
Jonathan W. Friedberg, MD, MMSc — University of Rochester Medical Center
Justin P. Kline, MD — University of Chicago
Ronald Levy, MD — Stanford University
David L. Porter, MD — University of Pennsylvania
Koen Van Besien — Weill Cornell Medicine
Michael Werner — Patient Advocate
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com